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strategies among which the decision maker must choose are
listed, the possible results of each of those strategies are
enumerated, and both the probability and the value the
decision maker attaches to each outcome are specified .
Decision analysis is reproducible : the analyst records the
strategies, results and values in the form of a tree
. Using this
record, the analyst, his or her colleagues and skeptics can
examine the influence of the data on the results . They can
distinguish important points of uncertainty from those that
have little influence . They can reformulate the structure of
the problem, revise the estimates used and examine the
effect of these changes on the decision .
In this article, we present a tutorial introduction to
clinical decision analysis and show how it can illuminate a
difficult, contruyersia
: question . Clinical decision analysis
consists of 1) problem formulation, 2) tree construction, 3
probability assessment, 4) utility assessment, 5) strategy
evaluation, 6) sensitivity analysis, and 7) interpretation . We
will illustrate this process with an example .
Problem formulation. The first step in decision analysis is
to formulate the clinical problem as a choice among several
alternative strategies that the clinician is considering .
The structure of a tree. With use of either pencil and
paper or microcomputer software (9), the second step is to
represent the strategies as a decision tree consisting of 1)
decision nodes, 2) chance nodes, and 3) terminal nodes. A
decision (square) node is a
point
is the tree where a choice
must be made (such as between medical or surgical therapy) .
Each branch emanating from a decision node represents a
different strategy . A chance (circular) node is a point in the
tree where the laws of probability determine the outcome of
events or the true state of the world. Examples of chance
events include the result of a test, the outcome of a treatment
and whether or not a patient has a disease. The branches of
both decision and chance nodes are assumed to be both
exhaustive and mutually exclusive, specifying all relevant
options and representing them explicitly . A terminal node
represents the consequence of one sequence of events of a
given strategy . Each terminal branch represents a unique
outcome state, which is assigned a value or utility . How each
state is valued depends on who the decision maker is and
what criterion he or she wants to use in selecting a strategy .
Probabilities. Each chance node represents the circum-
stance that one of several mutually exclusive chance events
has occurred or will occur . The analyst estimates the likeli-
hood or probability of each of these chance events . At any
chance node, the sum of these probabilities must, by defini-
tion, be unity
. To specify the probabilities we usually turn
first to the medical literature . If published data do not yield
usable data, if their applicability is uncertain or if the urgency
of the analysis precludes their detailed review, we estimate
probabilities subjectively or ask an expert's opinion .
Utilities
. Just as we must make explicit the probability of
clinical events, so too must we specify their relative value,
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or more precisely their utility, on some consistent scale .
First, we determine from whose perspective we are perform-
ing the analysis . Is it the patient's, the doctor's or the
payer's? We then choose the scale on which we will rate the
different outcomes . In medical decision analysis, quality-
adjusted survival has become a popular utility scale : life
expectancy, or average survival, is adjusted for short-term
and long-term morbidity . In our example we consider results
on three utility scales: short-term (1 month) survival ; long-
term survival ; and then two simultaneous scales, long-term
survival and cost, from which we calculate a cost/
effectiveness ratio. In this analysis we do not adjust for the
quality of the patient's life under different circumstances .
Specifically, we do not consider the effect of subsequent
angina, should it develop, on the quality of life .
Strategy evaluation . To compare strategies, we calculate
the value of each strategy by applying two simple rules . At a
decision node, the value of the node is the value of the best
strategy . At a chance node, the value is a weighted average of
the value of each outcome state (utility), where the weight
assigned to each state is the probability of arriving at that state .
Sensitivity analysis. Although choosing the best strategy
is important, decision analysis also allows us to ask "What
if?" and to substitute a range of values for one or more
probability or utility variables . Repeated recalculation of
results, which can be done very rapidly by a microcomputer,
shows how the expected utility of each strategy changes as
the value of these variables changes and whether the choice
among strategies is sensitive to the value of these variables .
Dual utilities . When one performs a decision analysis
from the perspective of an ik stitution or an individual who
pays for the treatment involved or from the perspective of
society (in which case we all pay), the analysis usually must
consider economic cost . When both costs and health out-
come benefits are considered together, there are two com-
mon approaches: cost-benefit analysis and cost-effectiveness
analysis . In cost-benefit analysis, all costs and benefits are
expressed in a single unit, usually in monetary units . In
cost-effectiveness analysis, costs (in dollars) and effective-
ness (typically in life-years) are considered separately and a
marginal ratio is calculated, that is, how much it will cost to
buy an additional unit of effectiveness or health output .
Some clinicians consider cost-effectiveness analysis more
congenial and intuitively more appealing than cost-benefit
analysis . Comparing the marginal cost/effectiveness ratios to
an explicit or implied willingness to pay allows one to choose
among alternative uses of limited health care resources and
to decide whether a given strategy is reasonable .
Example: Is Coronary Angiograp y
Necessary Before Aortic Valve Replacement?
A 63 year old woman has exertional syncope . She has no
history of chest pain, myocardial infarction or congestive
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heart failure and has physical, electrocardiographic (ECG
and echocardiographic findings typical of severe aortic sle-
nosis. Aortic valve replacement is recommended . Should
she undergo preoperative coronary angiography?
Brief review of the Nterature. Hemodynamically signifi-
cant aortic stenosis and coronary artery disease often coex-
ist . Among patients with aortic stenosis and angina pectoris,
the prevalence of coronary artery disease is 40% to 80%
(10, 11 . Because coronary artery disease increases the oper-
ative mortality of aortic valve replacement and shortens
long-term survival, there is general agreement that angina is
an indication for performing coronary angiography in prep-
aration for aortic valve replacement . However, in the ab-
sence of angina the issue is less cicao- . In. adu!ts with aortic
stenosis, aortic valve replacement is typically performed in
the sixth or seventh decade of life, when the prevalence of
coronary artery disease in the general population is 10% to
15% among men, and 5% to 10% among women (12 . Table
1 summarizes data rt. garding the prevalence of coronary
artery disease in patients with aortic stenosis who do not
have angina (11,13-19 .
Coexisting coronary artery disease increases the opera-
tive mortality of aortic valve replacement for aortic stenosis
Table 2. Operative MortaFay Rates
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Table 1 . Prevalence of Coronary Artery Disease (CAD) in Patients With Aortic Stenosis
but No Angina
(20-23 . Although this increased risk persisis even with cold
cardioplegia, concomitant coronary artery bypass grafting
modulated surgical mortality in several series (Table 2 .
Myocardial revascularization also improves long-term sur-
vival (20,21,23 , but patients free of significant coronary
disease will not benefit from a policy of universal coronary
angiography before aortic valve replacement . Recent Amer-
ican College of Cardiology and American Heart Association
guidelines (24 suggest performing coronary angiography
before aortic valve replacement in 1 a patient with angina or
ECG evidence of coronary artery disease, 2 all men >35
years old, and 3 all postmenopausal women . On the other
hand, at least one study (25 found no increase in operative
mortality despite omission of coronary angiography in pa-
tients with valvular heart disease, and some investigators
(26 argue that angiography is not universally necessary .
History, physical examination and the ECG do not , eli-
ably differentiate patients with aortic stenosis and coronary
artery disease from patients with aortic stenosis alone . In
theory, noninvasive testing might allow one to identify
patients likely to have coronary artery disease . But because
of the risk of hemodynamic collapse, the suspicion of severe
aortic stenosis is regarded as a contraindication to stress
With use of cold cardioplegia . AVR = aortic valve replacement
. CABG = coronary artery bypass grafting :
CAD = coronary artery disease .
Source (Ref.)
No . of
Patients
Definition of
Significant CAD
(% Stenosis
No. of Patients
Without Angina
No. (% of
Patients
Without Angina
but With CAD
Bermudez et al . (13) 64 >75% 13 7(54
Chobadi et al . (14) 146 >50% 39 9 (23
Exadactylos et al. (15) 88 >50% 88 0 (0
Graboys and Cohn (16) 19 >75% 19 0 (0
Hancock (17) 173 >50% 173 15(9
Miller et al . (I8) 91 >601/c 91 34 (37
Moraski et al. (11) 88 >50% 20 9(45
Paquay el al . (19) 76 >75% 19 1 (5
Total 745 462 75(16
No CAD CAD
AVE No CABG AVR + CABGAVR
Source (Ref.
No. of
Patients Deaths (%
No. of
Patients Deaths (%
No. of
Patients Deaths (%
Jones et al . (21 428 18(4 .2 51
9(17 .6 68 9(13 .2
Lytle et al . (22 272 3 (1, Up 23
1(4 .3
Lytle et al . (23
375 20(5 .3
Mullany et al . (20 73 I (1 .4 32
3(9 .3 99 4(4 .0
Total 773 22(2 .8 106
13 (12 .2 542 330.0
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No Catheterization
CAD
No CAD -->
AVR
Die a. Catheterization
CAD
Survive
No CAD
testing (27 . Nonetheless, such tests have been performed
with low complication rates (28 . However, the ECG re-
sponse to exercise does not discriminate well between
patients with aortic stenosis alone and patients with aortic
stenosis and concomitant coronary artery disease (29,30 .
A report (31 from Finland describes the use of thallium
imaging after dipyridamole injection and handgrip exercise
to detect coronary artery disease in patients with aortic
stenosis . The presence of perfusion defects could predict
z50% stenosis of at least one coronary artery with a
sensitivity of 85% and a specificity of 86% . These perfor-
mance characteristics are much like those of dipyridamole
thallium testing in the absence of aortic stenosis (32 . Two of
27 patients with aortic stenosis experienced symptomatic
hypotension after dipyridamole infusion that resolved during
handgrip exercise . During handgrip exercise, two others had
chest pain that responded to treatment ; there were no
deaths .
Problem formulation . In a 63 year old woman with char-
acteristic findings of aortic stenosis, no angina and no special
risk factors for coronary artery disease, should coronary
angiography be performed before aortic valve replacement?
Structure of the model. Figure 1 shows the structure of
the decision tree . The no catheterization and catheterization
strategies are represented as branches emanating from the
square decision node at the left . For the no catheterization
strategy, the first circular chance node represents the possi-
bility that the patient has coronary artery disease . This
chance node thus represents the current state of the patient .
Both the coronary artery disease and the no coronary artery
disease branches themselves lead to chance nodes that
represent whether or not the patient will survive aortic valve
replacement
. The terminal nodes at the extreme right repre-
sent possible consequences of the strategy
. The patient can
_-> AVR
-.-> AVR and CABG
AVR
Die
Survive
Die
Survive
Die
Survive
Die
Survive
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I
ALIVE with CAD without CABG
DEAD
ALIVE withoutCAD
I
DEAD
I
I
DEAD
ALIVE with CAD with CABG
DEAD
IALIVEwithout CAD I
Figure 1 . Decision tree including no catheterization and catheter-
ization strategies . AVR = aortic valve replacement ; CABG =
coronary artery bypass grafting ; CAD = coronary artery disease .
be dead, alive with coronary disease (but without coronary
artery bypass grafting or alive without coronary disease .
In the catheterization branch, the first chance node
represents the possibility of death at catheterization . If the
patient survives, the angiographic results (denoted by a
second chance node will determine whether or not she has
coronary artery disease . (In this case we can consider
coronary angiography a gold standard test because the
published -reports on prognosis in coronary artery disease
use angiography as a point of reference . Patients shown to
have coronary artery disease undergo coronary artery by-
pass grafting as well as aortic valve replacement .
Probabilities (Table 3 . We based the probability of cor-
onary artery disease in this asymptomatic 63 year old woman
on Diamond and Forrester s compilation of autopsy findings
in patients who died of noncardiac causes (12 . They noted a
close correlation between the autopsy prevalence data and
Framingham study findings on the 6 year incidence of
symptomatic coronary artery disease . Figure 2 summarizes
data sets and regressions on the autopsy data (linear for men,
exponential for women .
Short-Term Model
Severe aortic stenosis increases the risk of coronary
angiography slightly (33,34 . We used a value of 0 .002, twice
the overall mortality of coronary angiography . Operative
risks were based on the data in Table 2 . Efficacy is a number
between 0 and l that represents the extent to which an
JACC Vol. 15, No. 4
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Table 3 . Probabilities of Short-Term Events
14
12
if
10
U
19
0
•
	
6
•
4
0
Abbreviations as in Table 2 .
intervention prevents an undesired event . We define efficacy
as the following quantity : I - (frequency of event with
treatment + frequency of event without treatment . If the
treatment is completely effective, the event will not occur
with treatment, and efficacy will be 1 . If the treatment is
completely ineffective, the event will occur with the same
frequency with and without treatment, and efficacy will be 0 .
In Table 3 we calculate the efficacy of coronary bypass
surgery in reducing the mortality associated with aortic
valve replacement in the presence of coronary artery dis-
ease .
Utilities . We initially consider only short-term survival,
assigning a utility of I to patients alive after I month, and a
utility of 0 to patients who die within I month . On this scale,
Figure 2. Prevalence of coronary artery disease (CAD as a function
of age . For individuals dying a noncardiac death, closed squares
represent men and closed circles represent women . Regression lines
are plotted on autopsy prevalence data . Open squares (men and
open circles (women represent Framingham study predictions of the
incidence of coronary artery disease over 6 years . Data compiled by
Diamond and Forrester (12 .
LINEAR REGRESSION
LINE FOR MEN
35
45
Age
55
EXPONENTIAL REGRESSION
LINE FOR WOMEN
r
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Figure 3 . Sensitivity analysis for the short-term model : I month
surv;val as a function of the probability of coronary artery disease
(CAD and of age for men and women, respectively .
the calculated expected utility corresponds to the likelihood
of surviving the perioperative period .
Results of the short-term model . The no catheterization
strategy has an expected utility of 0 .966: the catheterization
strategy gives an expected utility of 0 .969. On the basis of a
0.2% difference in survival alone, it would be hard to
recommend either strategy in this 63 year old woman with
great conviction . However, plausible changes in our baseline
assumptions might cause the expected utilities of the two
strategies to diverge substantially . This brings us to sensi-
tivity analysis .
Sensitivity analyses : short-term survival . Although we es-
timated the probability of asymptomatic coronary artery
disease in this patient to be 0 .067, that value might substan-
tially vary for several reasons . For example, she might have
smoked, have been hyperlipidemic or hypertensive, or both,
or had a strong family history of coronary artery disease .
Figure 3 shows how a change in our estimate of the proba-
bility of coronary disease would affect the choice between
the two strategies . This sensitivity analysis shows the rela-
tion between the probability of I month survival (vertical
axis and the probability of coronary artery disease (upper-
most scale on the horizontal axis . As the probability that
coronary artery disease is present increases, the expected
survival rates of both strategies decline, because coronary
artery bypass grafting reduces, but does not eliminate, the
increase in operative mortality attributable to coronary
artery disease . Note that if the probability of coronary artery
disease is 0.032, the two strategies have the same expected
utility . We refer to the value of a variable at which two
strategies yield the same expected utility as a threshold. If
the probability of coronary artery disease is less than the
threshold, the no catheterization strategy is slightly better
; if
the probability is higher than the threshold, catheterization is
slightly better .
What if we erred in estimating the efficacy of coronary
artery bypass grafting in decreasing operative mortality
Variable
Baseline
Value
Probability of dying at angiography &W
Probability of CAD in a 63 year old woman 0.067
Probability of perioperative death
AVR alone, no CAD 0 .028
AVR with CAD, without CABG 0 .122
Excess AVR mortality attributable to CAD without CABG
mi22 - 0.028 0 .094
AVR with CAD and CABG 0 .061
Excess AVR mortality attributable to CAD with CA BIG
(0 .061 - OM8 0.033
Efficacy of CABG in !1° creasing probability of perioperative
death (I - 0.033/0 .094
0 .65
756
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Table 4.
Estimation of Long-Term Survival for a 63 Year Old Woman
Step 1
: Calculate average base annual mortality rate from life expectancy
1
	
l
= 0.05/year
Life expectancy
-
19.8
Step 2
: Calculate efficacy of CABG in decreasing excess annual CAD mortality
Excess Mortality Rates
Patient Characteristics
AS, CAD, CABG
AS, CAD, no CABG
0.039
Efficacy of CAI3G = I
-
i-.-0-87 = 0 .55
Step 3
: Calculate compound mortality rates for all possible outcomes
AS WithoLt CAD
AS With CAD
attributable to coronary artery disease? The threshold value
of efficacy at which catheterization and no catheterization
yield the same short-term survival is about 0 .31, less than half
our baseline value of 0 .65. On the other hand, even if the
efficacy of coronary artery bypass grafting were I (that is, if it
eliminated excess operative mortality attributable to coronary
disease , the difference in expected utility between the two
strategies would be only about 0 .004. Again, in the short-term
analysis for this patient, the difference in survival is small .
Age and gender. So far, we have analyzed this problem
with reference to a 63 year old woman . Using the regression
analysis shown in Figure 2, we extend the decision analysis
to women of other ages and to men (Fig . 3 . The two lower
scales on the horizontal axis show the ages for men and
women, respectively, that correspond to prevalence of cor-
onary disease shown on the upper scale . Among women
catheterization is the preferred strategy for those >57 years
old ; among men, for those >39 years old . Neither for men
nor for dvomen is the difference in l month survival more
than about 1% at any age .
Operative mortality may be substantially lower for
younger patients than for our index patient
. Coronary Artery
Surgery Study (CASS
data show that operative mortality
for coronary artery bypass grafting in a 35 year old womart is
Calculated from observed survival and expected survival based on age, gender and race . A S = aortic stenosis ;
other abbreviations as in Table 2 .
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about one third that for a patient in her 60s (35 . Diminishing
operative mortality by a factor of 3 for patients in their 40s
does not affect the ranking of strategies or significantly
change short-term survival .
Long-Term Survival: Representing
Life Expectancy
Short-term survival may not capture all of the potential
benefit a patient with significant coronary artery disease may
derive from concomitant coronary artery bypass grafting. By
revascularizing potentially ischemic myocardium, coronary
artery bypass grafting could diminish long-term excess an-
nual mortality from coronary disease. Of course, this addi-
tional benefit is speculative because we are considering
patients without angina .
To incorporate long-term survival into our model, we
must estimate the patient s life expectancy for each out-
come. Although this estimate could be made in several ways,
we used the Declining Exponential Approximation of Life
Expectancy (DEALE method (36,37 . This method com-
bines the base case average mortality rate (determined by
the patient s age, gender and race and the excess mortality
NoCABG CABG
Mortality rate
Average base annual rate
0.05 0 .05 0 .05
Excess with aortic valve
0.025 0 .025 0 .025
prosthesis [Jones et al .
(21 1
Excess with CAD 0 0.087 0.039
Total 0.075/yr 0.162/yr 0
.114/yr
Step 4 : Calculate life expectamies as reciprocals of compound annual mortality rates
8 .8 yrLife expectancy (I/total 13.3 yr 6.2 yr
Jones et al . (21
Czer et al . (19 Weighted Average
0.032 0.040 0.039
0 .085 0.089
0.087
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Figure 4. Two way
sensitivity analysis for the long-term model
:
effect of simultaneous changes in estimates of the short- and
long-term efficacy of coronary artery bypass grafting (CABG .
Short-term efficacy is efficacy in reducing operative mortality .
Long-term efficacy is efficacy in reducing excess annual mortality
attributable to coronary artery disease .
rates imposed by each of the patient s diseases . The DEALE
method estimates of long-term survival for our index case
are presented in Table 4 .
Results of the long-term model . The no catheterization
strategy has an expected utility of 12 .37 years and catheter-
ization has an expected utility of 12.53 years . On average,
performing coronary angiography is expected to lengthen
this patient s life by 1 .9 months or 1 .3% .
Sensitivity analysis : long-term survival . Although there is
little difference between the two strategies, for men cathe-
terization is favored over the entire age range, whereas for
women it is favored only above age 45 . Because of the
potential long-term survival benefit of coronary artery by-
pass grafting, there is no longer a threshold excess operative
mortality below which no catheterization is preferred . Sim-
ilarly, there is no threshold for the efficacy of coronary
artery bypass grafting in decreasing the excess operative
mortality .
To this point, we have presented one way
sensitivity
analyses, which show utility as a function of one variable . In
a two way
sensitiv y analysi  we examine th  conse-
quences of simultaneous variation of two variables
. For
example, what if both short-term and long-term efficacies of
bypass surgery differed from our base case? Might there be
some plausible combinations for which the no catheteriza-
tion strategy would be better? Figure 4 explores this issue .
The horizontal axis shows short-term efficacy, the vertical
axis long-term efficacy . Every possible combination corre-
sponds to a point in the plane. In effect, we calculate the
expected utility of both strategies for each such combination
and draw a line separating the region in which catheteriza-
tion has the higher expected utility from the region (the
shaded area
in wh ch no c theterization has th  high r
expected utility . Note that even if the short-term efficacy of
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0.2 -1
Age
0.6 40
L_ 70
0 0.1 0.2 0.3 0A 0.5 DA 0 .7 0.9 0.9 1 .0
Short Term Efficacy of CABG
Figure 5 . Three way
sensitivity analysis for the long-term model
:
lines representing women aged 40, 50, 60 and 70 years have been
substituted for the single line representing a 63 year old woman in
Figure 4 . Abbreviation as in Figure 4 .
cotaniry artery bypass grafting were 0 .31 (the threshold
value we determined in our short-term analysis
, long-term
efficacy would have to be less than 0 .07 for no catheteriza-
tion to be the strategy of choice (arrows .
We can add one more dimension, performing a tree
way
sensitivity analysis
. Figure 5 has the same axes, but
instead of one threshold line, we show a family of lines, each
corresponding to a different age . For example, for 40 year
old women catheterization would be preferred to no cathe-
terization only for efficacies corresponding to points above
the top line
; for 50 year old women catheterization would be
preferred for points above the second line down
.
Dipyridamole-Thalliiiin Testing
ayes
rule
. Even when we take the long-term benefit of
revascularization into account, the gain from catheterization
is small . Perhaps a strategy that includes a noninvasive
diagnostic test to stratify patients by likelihood of coronary
artery disease before catheterization would do better . Al-
though physicians sometimes think of a diagnostic test as
indicating the presence or the absence of a disease, tests are
imperfect and can produce false negative and false positive
results. If we estimate the likelihood of disease in a given
patient before knowing test results (the prior probability
and
if we know the likelihood of observing a test result in
patients with and without the disease (the conditional prob-
abilities , then we can revise our belief about the probability
of disease on the basis of the test result . An abnormal result
revises the probability upward, a normal result, downward
.
0
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The result is the posterior probability of disease, posterior
with respect to the test .
Bayes rule (8 formulates these relations precisely. It
allows us to combine the prior probability of disease with
test sensitivity (the probability that the test will give an
abnormal result in someone with disease and with test
specificity (the probability that the test will give a normal
result in someone without disease .
Consider the dipyridamole-thallium lest . The probability
of an abnormal test result in a patient with aortic stenosis
and substantial coronary artery disease (the sensitivity is
0.85. The probability of a normal test result in a patient with
aortic stenosis but without substantial coronary artery dis-
ease (the specificity is 0.86. Table 5 shows how Bayes rule
can be applied . The upper half of the table applies to an
abnormal test result ; the lower half applies to a normal
result. The table is organized into five columns . Column A
lists the diagnostic possibilities . Column B specifies the prior
probabilities
. Column C specifies the conditional probability
of the observed finding given each diagnosis
: in the case of
an abnormal test result, the sensitivity and the false positive
rate
; in the case of a normal result, the false negative rate
and the specificity
. Column D is simply the product of
columns B and C
. Finally, column D is summed and column
E calculated as the quotient of each entry in column D and
that sum
. The dipyridamole-thallium test result, if abnormal,
revises the probability of coronary artery disease upward
from 0.067 to 0.303 in our patient. The lower panel of the
table shows that a normal result would revise the probability
of coronary disease downward from 0
.067 to 0 .012 .
Sensitivity, or true positive rate ; tfalse positive rate (I - specificity ; #false negative rate (1 - sensitivity ;
§specificity or true negative rate .
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Having interpreted the results of a dipyridamole-thallium
test in the setting of aortic stenosis, we must decide whether
or not a strategy that stratifies patients on the basis of those
results is reasonable . We modify our decision tree (Fig . 1 by
adding a third strategy, dipyridamole-thallium screening .
Figure 6 shows the third strategy, incorporating informa-
tion from dipyridamole-thallium testing with handgrip exer-
cise . If the patient has an abnormal test result, she will
undergo catheterization, but the probability that substantial
coronary artery disease is present will be increased from
0.067 to 0.3. If the dipyridamole-thallium test results are
normal, she will undergo aortic valve replacement without
catheterization, but the probability that coronary artery
disease is present will be decreased from 0.067 to 0.01 .
Utility is once again measured in long-term survival .
Dipyridamole-thallium testing : results . In the base case
the dipyridamole thallium strategy has an expected utility of
12.51 years, still not quite as good as catheterization (12 .`3
years . Although the testing strategy spares 86% of the
patients without coronary artery disease the small risk of
catheterization (0.002 , that benefit is outweighed by its
failure to detect 15% of the patients who do have significant
coronary artery disease. Those patients would then be
exposed to a substantial excess risk (0.061 during aortic
valve replacement. For men, catheterization is preferred at
age >36 years . For women, however, there is a decade (43 to
53 years for which the dipyridamole-thallium strategy yields
the longest life expectancy. For women between 35 and 43
years, no catheterization is preferable ; for women >53 years
old, catheterization is best .
Table S. Effect of Dipyridamole-Thallium Testing on the Probability of Coronary Artery
Disease (CAD
Effect of Abnormal Test Result
A
	
B
C
C ;nditiona!
Probability
D E
Posterior or Revised
Prior
Diagnosis Probability
of Abnormal Test
Result
Product
(B x C
Probability
(D/sum
CAD 0.067
0.85 0 .057 0.057/0.188 = 0.303
No CAD 0 .933
0.14t 0 .131 0
.131/0.188 = 0 .697
Sum = 0.188
Effect of Normal Test Result
C
Conditional
Probability
D
E
Posterior or Revised
A
B
Prior
Diagnosis
Probability
of Abnormal Test
Result
Product
(B x C
Probability
(D/sum
CAD 0.067 0
.15 0,010 0 .010/0 .812 = 0 .012
No CAD 0 .933
0.86§ 0.802 0.8u210 .812 = 0.988
Sum = 0.812
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Figure 6. Decision tree with addition of the
dipyridamole-thallium strategy . Details of the
no catheterization and catheterization strate-
gies and abbreviation are as in Figure 1 .
Mujoicdveness Analysis
Whether we consider short-term or long-term survival,
the expected gain associated with catheterization is small
even if a noninvasive test were used to stratify patients . If
resources were unlimited, perhaps we would pursue the
practice that maximizes expected survival . But in 1990,
resources available for health care are limited . In the context
of that limitation, are these small gains worth the price?
Although we cannot answer this question in any absolute
sense, cost-effectiveness analysis puts the additional cost of
catheterization in perspective .
Life expectancy versus cost. We examined the three strat-
egies from a hospital s perspective, using life expectancy in
years as our measure of e6ectiveness and using variable
costs (not charges . At our hospital, the average variable
costs are approximately the following : dipyridamole-
thallium testing 250, catheterization 1,000, aortic valve
replacement without coronary artery bypass grafting 10,000
and aortic valve replacement
wits,
coronary artery bypass
grafting 11,000. Table 6 shows the calculations for our
index case. First we order the strategies (first column by
cost (second column , listing the effectiveness of each (third
column . Next we calculate the additional, or marginal cost
and effectiveness of each strategy and the marginal cost/
No Catheterization
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Survive
Table 6. Cost-Effectiveness (CE Analysis : Baseline Results for a 63 Year Old Woman
Calculated as marginal cost + marginal effectiveness and rounded off .
Probability of CAD higher
No CatheterizationTest Negative . .->
Probability of CAD lower
effectiveness ratios. Dipyridamole-thallium testing costs
480 more than no catheterization and provides 0 .14 years (7
weeks of additional life expectancy, for a marginal cost/
effectiveness ratio of
3,400 per year of life gained . Cathe-
teriz, ition costs 570 more than dipyridamole-thallium test-
ing ~ ad provides a survival benefit of 0 .02 years (1 .5 weeks ,
for a marginal cost/effectiveness ratio of 29,000 per year of
life saved .
Marginal cost/effectiveness ratios for awn and women as a
function of age (Fig. 7 . Each graph has two curves, one
c( mparing the dipyridamole-thallium and the no catheteriza-
6 n strategies and a higher one comparing the catheteriza-
tion and dipyridamole-thallium strategies . The curves for
glen and women are similar, but those for men are shifted to
the IeA; for any age, the cost/effectiveness ratio is lower for
men than for women . For each gender, as padents ages
decrease and approach, the threshold age at which marginal
effectiveness is 0, the marginal cost per life year gained by
pursuing dipyridamole-thallium testing rather than no cath-
eterization or catheterization rather than dipyridamole-
thallium increases sharply .
Cost/effectiveness ratios and willingness to pay. Strategies
with lower cost/effectiveness ratios are not necessarily bet-
ter strategies. To use the analyses summarized in Figure 7 to
Strategy
Cost
(
Survival
(yr
Marginal
Cost (
Marginal
Survival
(yr
Marginal CIE
Ratio ( /yr
gained
No catheterization 10,000 12.37
Dipyridamole-thallium testing 10,480 12.51 480 0 .14 3,400
Catheterization 11,050 12 .53 570 0 .02 29,000
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t
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Figure 7. Marginal cost-effectiveness of catheterization (OATH and
dipyridamole-thallium (DT , compared with no catheterization (NO
CATH and with each other for women (upper panel and men (lower
panel .
choose a strategy, the decision maker must specify a maxi-
mal willingness to pay . If resources were unlimited,
catheterization would be used in all men >36 years old and
all women >53 years old . But suppose society chose to
spend no more than 50,000 to save a year of life (broken
lines . In that case, catheterization would be used only in
men >41 years old and dipl,,ndamole-thallium testing in men
aged 35 to 41 years (lower panel . For women (upper panel ,
dipyridamole-thallium testing would be used in those aged
between 45 and 59 years, and catheterization would be used
in those >59 years old . Similar threshold ages could be
calculated for different levels of willingness to pay (Table 7 .
Table 7. Relation Between Willingness to Pay and Patient Age
JACC Vol
. 15, No . 4
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]Discussion
In this tutorial, we have outlined the technique of clinical
decision analysis, beginning with a specific patient and
generalizing to a clinical strategy . Because the data support-
ing several assumptions were quite uncertain, we used
sensitivity analyses to examine the quantitative importance
of simultaneous uncertainty regarding these variables .
At the most general level, decision analysis represents the
study of decision making under uncertainty . It allows us to
explore the possible implications of data despite uncertainty
regarding their precision . It gives us a consistent, reproduc-
ible method by which to integrate information regarding the
conflicting considerations that influence our decisions . It
allows us to structure problems . Most important, it forces us
to be explicit .
This analysis was developed as a didactic exercise and is
not sufficiently detailed to form the basis for a policy
regarding coronary angiography or noninvasive testing in
patients who are to undergo the replacement of a stenotic
aortic valve . Although careful, our review of the literature
was not exhaustive, and our model involves some obvious
simplifications . For example, we did not perform quality
adjustment for life with angina, if and when it begins, and we
did not represent the possibility that the patient might
subsequently require reoperation or percutaneous translu-
minal angioplasty for coronary artery disease .
However, even this simplistic but explicit model does
provide insights into the dynamics of the problem of aortic
stenosis and po-,sible coronary disease . Except among the
youngest of the 35 to 65 year old men and women to whom
we generalized the analysis, coronary angiography provides
a very modest increase in long-term survival . However,
even for 65 year old men, average survival with catheteriza-
tion would be only 3 months longer than with no catheter-
ization. This 2 .7% prolongation of a life expectancy of 9 .5
years is surely a close call (38 .
Use of a dual utility scale . Introducing a dual utility scale
that incorporates cost offers several new perspectives on
these small survival gains . First, it offers another criterion by
which to distinguish small survival differences . For some
patients, the small survival gains cost a few thousand dollars
per additional life-year ; for others, they will cost tens or
hundreds of thousands of dollars .
Second, cost-effectiveness analysis shows that a strategy
that provides intermediate benefit at intermediate cost may
be worth further study. Although dipyridamole-thallium
testing does not provide a survival advantage over catheter-
ization, it may provide a substantial part of the survival
advantage of catheterization at a lower cost.
A third and corollary observation is that introducing
dipyridamole-thallium testing into the cost-effectiveness
analysis increases the marginal cost/effectiveness ratio of the
more expensive and more effective strategy, catheterization .
Men
20,000
35-52
>52
50,E
35-41 >41
100.000
35-39 >39
women
20,000
<49
49-65
>65
51,E
<45
45-59 >59
100,000
<44
44-56
>56
-~ Dipyridamole-
No Thallium
Willingness to Pay
Catheterization
Testing Catheterization
151yr gained (age . yr
(age, yr
(age, yr
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Table 8 . Marginal Cost Effectiveness
Inflated to 1989 dollars using the consumer price index . Abbreviations as
in Tables 2 and 6 .
If we compare only catheterization and no catheterization,
the marginal cost of an additional year of life gained by
performing coronary angiography on a 40 year old man
would be 9,300. If dipyridamole-thallium testing is an
option, the marginal cost of a year of life gained by angiog-
raphy would be almost 61,000.
Fourth, cost-effectiveness analysis shows the relation
between willingness to pay (39 , that is, the maximal accept-
able cost/effectiveness ratio, and threshold ages for cathe-
terization and dipyridamole-thallium testing . One could set
such payment levels by direct questioning, by consensus or
by using the Delphi technique (40 . Alternatively, one can
examine currently accepted therapies and tests to see what
the implied willingness to pay threshold might be (Table 8
(41-46 . For example, a 20, /year threshold would en-
dorse neither coronary artery bypass grafting for single
vessel disease nor cardiac transplantation, but would allow
renal transplantation, coronary artery bypass grafting for left
main coronary artery disease and coronary angiography in
asymptomatic men >52 years old as a prelude to aortic valve
replacement .
Conclusions . In our illustrative problem, analysis using
the dual utility scales of cost and effectiveness yielded
results more striking than those of analysis of survival alone .
Although it is not the only voice we should hear, cost-
effectiveness analysis has much to tell us about the rational
allocation of limited resources . It does not follow, however,
that a cost-effectiveness analysis is more important or more
correct than an analysis that examines survival or cost alone .
Furthermore, an economic perspective is neither appropri-
ate nor required in every clinical decision analysis . Although
decision analysis can recommend strategies, it is the deci-
sion maker who prescribes the perspective and the utility
scale. In making explicit our choice among perspectives and
GEORGESON E
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the tradeoffs that choice itlapli s, clinical decision analy s
e s
can help us articulate the contradictions in society s expec-
tations of medical care .
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